Comment on ‘Efficacy and safety of vismodegib in basosquamous carcinoma: insights from a retrospective study including 18 patients’: basosquamous carcinoma at the crossroads: histological ambiguity, treatment potential and the path to clinical consen

Basosquamous carcinoma (BSC) remains a histologically and clinically challenging entity, with emerging data supporting the efficacy of vismodegib even in the presence of squamous differentiation. Our commentary builds on a retrospective analysis showing a 94.4% response rate to vismodegib in locally advanced BSC and integrates findings from our national UK survey study on the management of BSC, which highlighted variability in classification, surgical margins and treatment approaches. Together, these contributions underscore the urgent need for consensus guidelines, standardized diagnostic criteria and prospective studies to optimize management of BSC.